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ceptually challenging. A desire to provide a complete ranking from best to worst
was observed. The majority (18,75%) of participants indicated a preference for DCE,
as they felt this enabled comparison of alternative full profiles. Of those preferring
BWS (3,50%) indicated the primary reason was related to the ability of BWS to
remove the potential requirement to choose an undesirable characteristic that was
part of a ‘package’, (1,17%) perceived the BWS to be less ethically conflicting, and
(2,33%) perceived BWS to be less burdensome. More participants were consistent
for the DCE (22,92%) than BWS (10,42%) repeated task (p0.002); for BWS, lack of
consistency was not observed to be associated with the choice (best or worst).
CONCLUSIONS: This novel study supports the validity and acceptability of DCE
methods for assessing preferences. The findings relating to the application of BWS
profile methods are less definitive than for the traditional choice task. However,
important avenues for future research to further clarify the comparative merits of
DCE and BWS preference elicitation methods are identified.
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OBJECTIVES: Schizophrenia is a psychiatric illness that associates thought process
disintegration and poor emotional responsiveness. The S-QoL is a self-adminis-
tered questionnaire that assesses quality of life (QoL) among people with schizo-
phrenia. The scale is a 41-item questionnaire with eight subscales (psychological
well-being, self-esteem, family relationships, relationship with friends, resilience,
physical well-being, autonomy and sentimental life). The objective of this study
was to validate the Russian version of S-QoL. METHODS: The scale was of instru-
ment used in a clinical trial with 260 patients. Statistical examinations covered
factor analysis, internal consistency of subscales, construct and discriminant va-
lidity. The reproducibility (Test-retest) was assessed with patients whose clinical
global impression (CGI) improvement score declared unchanged between baseline
and endpoint (10weeks), whereas patients whose health status was improved are
used to evaluate the sensitivity to changes. RESULTS: The sample is composed of
subjects from Russia with 53% of female. Cronbach’s alphas were estimated to be
higher than 0.77. Factor analyses demonstrated the same structure as the French
version. Item internal consistency (IIC) and item discriminant validity criteria were
met for most items (i.e. IIC was  0.40, and correlations between items and their
respective rest-scores in one dimension were all greater than correlations with
another dimension). For the subgroup with no CGI improvement (56 patients out of
260), Test–retest demonstrated a highly correlation (range 0.49-0.79) between the
two assessments. Assessing the sensitivity on the subgroup of 161 patients for
whom an improvement was declared (mean change  1.47), a significant differ-
ence was found for the global score and for all dimensions except the psychology
dimension. CONCLUSIONS: Overall, the S-QoL, which has sound psychometric
properties, is a valid instrument for measuring the disease specific HRQoL of pa-
tients with schizophrenia in Russia.
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OBJECTIVES: Type 2 diabetes mellitus(DM2) and polypharmacy can affect the
health related quality of life(HRQoL). A new 5-level version of EQ5D instrument is
available; it is therefore interesting to evaluate its performance compared to pre-
vious EQ5D-3L. METHODS: Cross-sectional study of baseline data from a cohort of
DM2 patients taking 5 or more drugs (313 patients from a randomized clinical trial
to prevent drug inadequacy in DM2 patients). HRQoL was measured using EQ5D-5L
instrument and compared to previous EQ5D-3L data from a similar population.
Patient socio-demographic data, number and nature of prescribed drugs and
HbA1c serum levels were collected; their associations to variations in HRQoL were
assessed. EQ5D-5L utilities were elicited thru 5L-3L EuroQoL crosswalking value
set. Cronbach’s alpha was used to evaluate reliability of EQ5D-5L in this sample,
and Spearman’s rho coefficient for correlations. RESULTS: Mean age at index date
was 71 years, 57.2% were male and 75.7% were 65 years or older. Mean HbA1c was
7.2%[SD:1.3], 22.4% were taking insulin and 51.6% had a good control of their dia-
betes. On average patients were taking 9.4 drugs[SD:3.8; range:5-23]. Most affected
EQ5D dimensions were mobility and pain/discomfort (more than half of respon-
dents reporting problems). Mean EQ5D utility index was 0.786[SD:0.224; range:
0.224 to 1]. Bad glycemic control (HbA1c7%), use of insulin and a greater number
of drugs were all associated to a poorer HRQoL. EQ5D index was negatively corre-
lated with the number of prescribed drugs(r0.34; p0.01), but no correlation was
found with age or HbA1c. EQ5D-5L showed good reliability (0.77) and less ceiling
(23.3%) and floor (0.3%) effects than 3L. There was a better discrimination capacity
for punctuations in each of the 5 dimensions. CONCLUSIONS: DM2 patients with
polypharmacy showed a diminished HRQoL, negatively correlated to the number of
prescribed medicines; the new EQ5D-5L appears to exhibit better discriminatory
properties than the traditional EQ5D-3L.
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are two com-
mon tools for the direct elicitation of health utilities, the prevailing quantitative
unit for the evaluation of health-related quality of life (HRQoL) in a given popula-
tion. These tools may be administered to patients for the assessment of their
current HRQoL. Comparisons between TTO and SG outcomes for a patient popula-
tion were explored in the present systematic review of primary evidence from
published studies. METHODS: A systematic review of the literature was under-
taken in Ovid Medline® to identify all publications in English since 1996 reporting
both mean TTO and SG outcomes in the same patient population, on their current
HRQoL. The literature search and data extraction were independently undertaken
by two researchers, using a pre-determined set of inclusion/exclusion criteria to
generate a list of relevant publications, with a third researcher acting as adjudica-
tor in case of disagreement. Excluded were reviews or non-original publications, as
well as publications reporting health utility outcomes of hypothetical health states.
Data were analyzed on study arms (studies) for differences and/or correlation be-
tween the TTO- and SG-derived utilities. RESULTS: The initial literature search
identified 170 articles which yielded 56 relevant publications encompassing 26
disease categories, 79 studies and a total of 11,090 patients. The most common
disease category, discussed in 18 studies covering 2,258 patients, was ocular dis-
ease. The overall weighted mean utility scores were 0.82 and 0.85 for TTO and SG
respectively, with 61% of studies reporting higher utility scores with SG and 6%
equal results. Overall, 22% and 33% of studies displayed greater than 10% absolute
and relative difference between the two measurement tools, respectively. Spear-
man’s rho yielded significant positive correlation (r  0.586). CONCLUSIONS: The
majority of studies displayed little difference in scores between TTO and SG, with
significant correlation observed overall.
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OBJECTIVES: To explore the ability (validity) of the OAB-V8 screening scale to pre-
dict changes in patient’s HRQoL and severity of symptom bother (SB) in subjects
with symptomatic OAB treated with antimuscarinic drugs in daily practice in clin-
ics of Urology. METHODS: Patients, both genders, 18 years, with symptomatic
OAB [score8 in OAB-V8 scale] and able to understand and fill-in PRO instruments
written in Spanish were enrolled in this study. The culturally adapted and vali-
dated Spanish version of OABq-SF was administered twice 3 months apart to pa-
tients recruited consecutively at clinics of Urology all over the country and who
were prescribed a treatment with an antimuscarinic drug according to usual prac-
tice. Patients were compared in the OABq-SF: SB and HRQoL scorings. To test the
predictive validity of the OAB-V8 scale, baseline scores were included in multivar-
iate regression models along with age, symptoms duration, age at the initiation of
symptoms, body mass index, and generic HRQoL (assessed with EQ-5D) as covari-
ates to predict changes in OABq-SF dimensions from baseline to follow-up at
3-months period. RESULTS: The study enrolled 246 OAB symptomatic patients
(mean age 57.7 years, 67% women, 99% Caucasian, 37% active workers, 36% pri-
mary schooling). OAB-V8 scores significantly correlated (Pearson’s r coefficient)
with OABq-SF domains;0.790 and0.659 for SB and HRQoL domains, respectively
(p0.001 in both cases) indicating a possible linear relation. Multivariate regression
models showed OAB-V8 baseline score being able to predict changes in both do-
mains of the OABq-SF; R2 0.212 and 0.162 in severity of SB and HRQoL, respec-
tively. OAB-V8 coefficients were significant in the two models with  coefficients of
0.421 (p0.001) and 0.340 (p0.001), respectively. CONCLUSIONS: The OAB-V8
scale provided evidence of predictive validity of self-assessment quality-of-life and
severity of symptoms bother changes in patient with OAB treated with antimus-
carinic drugs in routine medical practice.
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are two meth-
ods for the direct measurement of health-related quality of life (HRQoL) in a pop-
ulation. These tools may be used not only in patients but also to evaluate the
general public’s preference for a particular health state. The purpose of this study
was to undertake a systematic review of the literature comparing TTO and SG
outcomes for the general population. METHODS: Ovid Medline® was scoured to
gather original studies published in English since 1996 reporting both mean TTO
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